-
Mashup Score: 2Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC - 14 hour(s) ago
Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting - 2 day(s) ago
The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Treatments are rapidly evolving in the second-line setting and beyond for patients with HER2-mutated NSCLC, with several promising TKIs under development looking to join T-DXd in this setting. #lcsm #oncology https://t.co/XWoVbEp1DV https://t.co/xhVVD2gQ9s
-
-
Mashup Score: 4Northwestern Medicine Performs the Highest Number of Lung Transplants in the United States - 4 day(s) ago
The Canning Thoracic Institute became the highest-volume lung transplant center in the US and achieved the shortest wait time for a lung transplant.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Northwestern Medicine Performs the Highest Number of Lung Transplants in the United States @AnkitBharatMD @Arunachalam_md @NM_Lung @NorthwesternMed @NUFeinbergMed #lcsm #oncology https://t.co/z5N4om1DHo
-
-
Mashup Score: 7
THIO plus cemiplimab generated a potential survival benefit in pretreated advanced non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
THIO Plus Cemiplimab Demonstrates Potential OS Benefit in Pretreated Advanced NSCLC #lcsm #oncology https://t.co/NtorpmNu44
-
-
Mashup Score: 3
Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung @US_FDA #lcsm #oncology https://t.co/Pu2BJbl2EK
-
-
Mashup Score: 4REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point - 13 day(s) ago
The REZILIENT1 study of zipalertinib in pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations met its primary end point of ORR.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point #lcsm #oncology https://t.co/aY13QQSy4X
-
-
Mashup Score: 3
Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung @US_FDA #lcsm #oncology https://t.co/Pu2BJbl2EK
-
-
Mashup Score: 6
The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC #lcsm #oncology https://t.co/L7vAc9akW2
-
-
Mashup Score: 7Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - 22 day(s) ago
China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification #lcsm #oncology https://t.co/vQR8ttBKLd
-
-
Mashup Score: 17European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC - 22 day(s) ago
The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC #lcsm #oncology https://t.co/rnyydMjSx0
-
Tissue NGS-based HER2, KRAS, and MET copy number gain thresholds that were set by oncogene overlap identified potential clinically relevant amplified subgroups of NSCLC tumors with altered genetic profiles. @AlexWatsonMD @CUAnschutz #LCSM #oncology https://t.co/tAh9gxr4Ya https://t.co/rjVQNsmxyZ